Keymed Biosciences, Inc. (HK:2162) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Keymed Biosciences Inc. has entered an exclusive license agreement with Platina Medicines Ltd, granting them rights to develop, manufacture, and commercialize the bispecific antibody CM336 outside China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of $16 million to Keymed and potential milestone payments up to $610 million, along with royalties on sales. This agreement aims to expand Keymed’s global presence and maximize the commercial potential of its technology.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Upcoming Stock Splits This Week (November 18 to November 22) – Stay Invested
- Alibaba to Raise $5B in Dual Currency Bonds Following Solid Q2 Print
- Nvidia’s Latest Blackwell Chips Are Overheating and Customers Are Worried
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
